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Abstract
Background: Non-small cell lung cancer (NSCLC) is one of the most aggressive types of cancer. However,
resistance to cisplatin (CDDP) remains a major challenge in NSCLC treatment. The purpose of this study was to
investigate the ability of EHD1 [Eps15 homology (EH) domain - containing protein 1] to confer CDDP resistance in
NSCLC cells and to investigate mechanisms of this resistance.
Methods: The associations between EHD1 expression in NSCLC specimens and clinicopathological features, including
prognosis, were assessed by immunohistochemistry (IHC). Using DNA microarrays, we performed a genome-wide analysis
of cisplatin-resistant NSCLC cells to identify the involvement of the EHD1 gene in this resistance. We overexpressed and
knocked down EHD1 in cell lines to investigate the effect of this gene on proliferation and apoptosis. A quantitative
analytical method for assessing CDDP in cells was developed. High-performance liquid chromatography was used to
measure the concentration of cisplatin in cells.
Results: The immunohistochemistry assay showed that adjuvant chemotherapy-treated NSCLC patients
expressing EHD1 exhibited reduced OS compared with patients who did not express EHD1 (P = 0.01). Moreover,
DNA microarrays indicated that the EHD1 gene was upregulated in CDDP- resistant NSCLC cells. The IC50 value
of CDDP in cells that overexpressed EHD1 was 3.3-fold greater than that in the A549-control line, and the IC50
value of EHD1 knockdown cells was at least 5.2-fold lower than that of the control cells, as evidenced by a CCK-8
assay. We found that the percentage of early apoptotic cells was significantly decreased in A549-EHD1 cells, but
the rates of early apoptosis were higher in the EHD1 knockdown cell line than in the A549/DDP control line, as
indicated by a flow cytometry analysis. High-performance liquid chromatography (HPLC) showed that the total
platinum level was lower in A549-EHD1 cells than in control cells, and the concentration of CDDP was higher in
the EHD1 knockdown cells than in the A549/DDP control cells.
Conclusion: We conclude that EHD1 is required for tumour growth and that it is a regulator of CDDP
accumulation and cytotoxicity. The selective knockdown of EHD1 in tumours offers a strategy for enhancing the
efficacy of CDDP.
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Background
Lung cancer is one of the most devastating types of
cancer and poses a serious threat to human life and
health [1]. Specifically, it is the leading cause of cancer-
related morbidity and mortality worldwide [2]. Non-
small cell lung cancer (NSCLC) is the most common
form of lung cancer and accounts for 80–85 % of all di-
agnosed lung cancers with a 5-year survival rate of
15 % [2]. Cisplatin (CDDP) is a component of standard
treatment regimens for NSCLC [3], and adducts of
CDDP with DNA induce apoptosis [4, 5]. However,
many patients develop resistance during sequential cy-
cles of treatment with CDDP, and this resistance under-
mines the efficacy of CDDP [6]. Drug mechanisms are
complex and include decreased drug accumulation, in-
creased drug efflux, altered oncogene expression, the
activation of detoxification systems, impaired apoptosis
and changes in the targets of the drug [7]. Recent stud-
ies suggest that many CDDP-resistant cells show de-
creased CDDP accumulation, and the identification of
specific proteins for drug resistance should provide tar-
gets for therapy aimed at circumventing or decreasing
CDDP resistance.
Cells internalize extracellular material, segments of
the plasma membrane and cell surface receptors by
endocytosis [8–10]. The C-terminal EPS15 homology
(EH) domain (EHD) is a highly conserved family of
proteins involved in endocytic trafficking [11]. This
family consists of four highly homologous members
in mammalian cells, EHD1-4 [12]. EHDs contain an
ATP- binding motif, a central coiled-coil and a C-
terminal EH domain that binds to proteins containing
the tripeptide asparagin-proline-phenylalanine (NPF)
[13]. EHD1 is the best characterized of the four EHD
proteins [11] and has been demonstrated to play a
role in regulating the recycling of receptors from the
endocytic recycling compartment (ERC) to the plasma
membrane [11]. EHD1 also plays a role in the trans-
port of receptors from the early endosome (EE) to
the ERC [11]. Moreover, EHD1 is also involved in
retrograde transport from endosomes to the Golgi
complex [11]. However, only a few studies have ana-
lysed the function of EHD1.
In this study, two independent cell lines that in
which EHD1 was stably overexpressed or knocked
down were established. The mechanism underlying
EHD1-dependent CDDP resistance in NSCLC cells
was investigated. Overall, our results suggest that
EHD1 is a CDDP-resistant gene that suppresses DNA
adduct-induced apoptosis by modulating intracellular
CDDP concentrations. The present study sought to
examine a novel therapeutic strategy to target CDDP-
resistant lung cancer and provide theoretical evidence
for the clinical application of this strategy.
Methods
Clinical tissue samples and IHC
The FFPE specimens of 59 patients with histologically
confirmed NSCLC treated at the Harbin Medical Uni-
versity Cancer Hospital from 2006 to 2007 as well as
their available clinical and follow-up information were
examined in this study. All patients underwent surgical
resection followed by three to four cycles of platinum-
based adjuvant chemotherapy. This study was approved
by the Institutional Review Board of the Harbin Medical
University Cancer Hospital. All patients had to have pro-
vided written informed consent.
The sections were deparaffinized, autoclaved, treated
with hydrogen peroxide solution, incubated with anti-
EHD1 rabbit polyclonal antibody (Abcam) at a dilu-
tion of 1:50 overnight at 4 °C. A streptavidin–biotin
complex system was used for staining. OS (overall
survival) was calculated as the time to death from the
date of diagnosis. Survival curves for OS were esti-
mated with the Kaplan–Meier method and compared
with the log-rank test [1, 9].
Gene expression microarray
Fresh tumour tissues from 205 patients with NSCLC
were obtained from the Harbin Medical University Can-
cer Hospital. Each patient had signed informed consent
for tissue sample donation and medical record review
before surgery. This study was approved by the Institu-
tional Review Board at Harbin Medical University Can-
cer Hospital. The tissues were then stored in RPMI-1640
for the primary culture of NSCLC cells. None of the pa-
tients had received neoadjuvant chemotherapy or radi-
ation therapy at the time of surgery. In total, 199 tissue
samples were tested for chemosensitivity with an MTT
(Sigma) assay. The samples with the highest sensitivity
or resistance to all of the 5 drugs (NVB, GEM, DOC,
TAL, CDDP) were selected. Total RNA was then ex-
tracted (TRIzol, Invitrogen), and the RNA purity was
assessed with a BioAnalyser 2100 instrument (Agilent).
Gene expression was profiled using a Human Genome
U133 Plus2.0 Affymetrix array (Santa Clara) according
to the manufacturer’s instructions. Total RNA was
reverse-transcribed using an RNA amplification kit
(Ambion), which was then hybridized, washed and
stained before scanning the chips. The mean SD of repli-
cate spots was calculated for each gene using the Acuity
4.0 software (Molecular Devices) [7].
Cell lines and cell culture
The human lung adenocarcinoma cell line A549 was
cultured in RPMI-1640 medium (Gibco), supplemented
with 10 % foetal bovine serum (FBS, Gibco) and 1 %
penicillin-streptomycin (HaiGene). The cells were main-
tained at 37 °C in a humidified atmosphere of 5 % CO2,
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and A549 cells were then selected for resistance to cis-
platin. A series of cisplatin-resistant A549 populations
(A549/DDP) were selected by stepwise increases in the
cisplatin (Sigma) concentration from 0.3 μg/ml to
20 μ g/ml over a period of 8 months [14, 15]. EHD1 was
then stably overexpressed or knocked down in tumori-
genic cells or in CDDP-resistant cells using lentiviral ex-
pression vectors. The lentiviral expression vectors were
purchased from HaiGene. The sequence of the EHD1-
shRNA was 5′- CGCTTTCCTCAACAGGTTCATTT
CAAGAGAATGAACCTGTTGAGGAAAGCG-3′. Len-
tiviral transfection was performed according to the
methods described by the manufacturer (HaiGene). The
cells were then cultured in the above culture medium
containing Puromycin (Sigma) 0.5 μg/mL. Transfection
efficiency was monitored by measuring the level of EHD1
mRNA using quantitative reverse transcription–polymer-
ase chain reaction (RT– PCR) or immunofluorescence.
RT-PCR assay
Total RNA was extracted from cultured cells using the
OMEGA Kit following the manufacturer’s instructions.
Total RNA was used to synthesize cDNA (Reverse Tran-
scription Kit, Roche). The newly synthesized cDNA was
then amplified by RT-PCR. Real-time PCR was per-
formed on the Applied Biosystems 7500 Fast Real Time
PCR System. The expression of indicated genes was
assessed by PCR using the following primers: for EHD1
— 5-CCAAGGTTCACGCCTACATC-3 (forward), 5-TC
TCCCAGGTTGTTCACCAG-3 (reverse); primers were
purchased from Sangon Biotech. The mRNA expression
level of EHD1 was calculated using the comparative
threshold cycle (CT) method and normalized to the ex-
pression of GAPDH (Life Science).
Immunofluorescence
Cells were cultured on cover slips for 24 h and then
fixed with 4 % paraformaldehyde for 20 min and perme-
abilized with 0.2 % Triton X-100 for 10–15 min at room
temperature. After washing with PBS, the cells were
blocked with normal goat serum for 30 min. The cells
were then incubated with antibodies (Proteintech) spe-
cific to EHD1 diluted at 1:50 overnight at 4 °C, followed
by secondary antibody incubation with Alexa Fluor 488-
labeled Goat Anti-Rabbit IgG (Beyotime) for 1 h and
staining with DAPI (Beyotime) for 5 min at room
temperature. The stained cells were mounted in antifade
mounting medium (Beyotime) and visualized under a
fluorescence microscope.
Cell viability assay
The cells were seeded in 96-well plates (8,000 cells per
well) and incubated overnight. After attachment, the
cells were treated with various concentrations of CDDP
for 24 and 48 h; cells treated with only RPMI-1640
medium served as controls. After cisplatin treatment,
10 μL of CCK-8 (Dojindo) was added to each well at
37 °C in the dark. After 3 h, the absorbance was mea-
sured at 450 nm using an Microplate Reader (BioTek).
The IC50 values were determined using the IBM SPSS
Statistics 19 software.
Western blotting
Cells were harvested with trypsin, pelleted by centrifuga-
tion at 4 °C and disrupted in cell lysis buffer (Roche) on
ice for 15 min. The protein concentration was deter-
mined with a BCA Protein Assay Kit (Thermo) as de-
scribed in the manufacturer’s manual. Protein lysate
(50 μg) was subjected to sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis (SDS-PAGE) and electro-
phoretically transferred to a polyvinylidene difluoride
membrane. After blotting, the membrane was incubated
with a specific primary antibody (EHD1: Proteintech;
GAPDH: ZSGB-BIO) at 4 °C overnight. After washing
with TBST (TBS containing 0.05 % Tween 20), the
membrane was incubated with secondary antibodies
(1:10000; ZSGB-BIO) for 1 h at room temperature.
Protein bands were visualized using a Super ECL Re-
agent (HaiGene), and the protein expression was
quantified by densitometry.
Flow cytometry
Cells were plated in 6-well plates and incubated over-
night. After attachment, the cells were treated with vari-
ous concentrations of CDDP for 24 h. For flow
cytometry, cells were harvested and labelled using an
Annexin V FITC/propidium iodide (PI) apoptosis detec-
tion kit (BD) according to the manufacturer’s instruc-
tion. At least 500,000 cells were analysed per sample.
Apoptotic cells were quantified using a flow cytometer
(BD FACSCalibur). Cells that were Annexin V+/PI- were
considered to be in the early apoptotic stage.
High-performance liquid chromatography
CDDP was dissolved in a 0.9 % (w/v) sodium chloride
solution (1 mg/ml), which was used as the stock solution
for HPLC analysis. Each standard solution for HPLC
analysis was prepared by diluting the stock solution con-
secutively with 0.9 % (w/v) sodium chloride solution.
The cells were treated with various concentrations of
CDDP. The lysed cells samples were centrifuged at 4 °C
for 15 min at 13000 rpm. The cell samples were added,
mixed with Na2CO3 and NaOH (5 % DDTC, v/v), vor-
texed briefly, and incubated at 37 °C for 30 min. The cell
samples were precipitated by the addition of ether-
chloroform-isopropanol and centrifuged at 4 °C for
5 min at 10000 rpm; the supernatant was discarded. All
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samples were frozen and stored below -20 °C until
analysis.
The Shimadzu 10AT HPLC apparatus was operated at
a wavelength of 254 nm. Solutions were injected into an
ODS Hypersil column (Agilent technologies) using an
autosampler (Shimadzu) and eluted using two pumps.
The mobile phase was methanol-water (80:20, v/v),
which was supplied at a constant flow-rate of 1.0 ml/
min. The chemicals used to prepare the mobile phase of
the chromatographic system were of HPLC grade, and
all other chemicals were of analytical grade. All other
chemicals and reagents were purchased from BOSTER.
A constant injection volume of 20 μL was used through-
out the study, and the baseline was set to zero after the
injection of the sample [16].
Statistical analysis
The data were statistically analysed using Student’s t-test
or the χ2 test with GraphPad Prism 6.0, and P < 0.05 was
considered to indicate significant differences. All experi-
ments were repeated three times, and representative
data are shown. *P < 0.05, **P < 0.01, ***P < 0.001.
Results
EHD1 correlated with the poor clinical outcome of NSCLC
To determine the roles of EHD1 in the clinical behav-
iour of NSCLC, we first used an IHC assay to profile
EHD1 expression in FFPE specimens from 59 patients
with NSCLC. EHD1 expression significantly differed by
histological type (P = 0.001) (60.47 % of adenocarcinoma
samples expressed EHD1, whereas 12.50 % of squamous
cell carcinoma expressed EHD1) and sex (P = 0.006)
(Table 1). EHD1 expression in NSCLC did not correlate
with age, smoking status, differentiation, and stage
(AJCC). EHD1 was expressed in 47.46 % NSCLC sam-
ples (Fig. 1, Table 1). Specifically, EHD1 was not
expressed in CDDP-sensitive cases (Fig. 1a and b) but
highly expressed in the NSCLC tissues of the CDDP-
resistant cases (Fig. 1c and d). The OS of the adjuvant
chemotherapy-treated patients with negative EHD1 ex-
pression was significantly longer than that of patients
with positive EHD1 expression (P = 0.01) (Fig. 1e).
A gene expression microarray was used to analyse 5
samples exhibiting the highest resistance and 6 samples
exhibiting the highest sensitivity to CDDP, and fold
changes in gene expression were analysed by SAM. A
fold-change in EHD1 expression of at least 1.2906 ± 0.07
was considered to be differential expression, but this dif-
ference was not significant (Table 2). Compared with the
CDDP-sensitive group, EHD1 was upregulated in the
chemotherapy-resistant group. These results suggested
that the up-regulation of EHD1 might confer resistance
to CDDP in NSCLC patients.
EHD1 overexpression and knockdown at both the protein
and transcript levels using lentiviral expression vectors
EHD1 was confirmed at both the transcript and protein
level in A549 and A549/DDP cell lines (Fig. 2a and b).
The localization of EHD1 protein expression in NSCLC
cell lines was examined by fluorescence microscopy in
living cells. EHD1 was localized in the perinuclear re-
gion, yielding a ring-like pattern (Fig. 2c-h). Whereas a
diffuse green fluorescence signal due to EHD1 was ob-
served throughout the entire cell in A549-EHD1 cells,
the overexpressed EHD1 was predominantly localized in
the cytoplasm, forming a ring-like pattern at the nuclear
periphery in cells that stably expressed EHD1 (Fig. 2e).
EHD1 overexpression was confirmed at the transcript
level (Fig. 2i). To evaluate the effect of EHD1 on cis-
platin resistance, we knocked down EHD1 using shRNA.
The A549/DDP cells were transfected with a shRNA-
EHD1 and analysed by immunofluorescence microscopy.
EHD1 expression detected by the EHD1 antibody con-
sistently displayed a peri-nuclear staining pattern, but
the EHD1 levels are significantly decreased in A549/
DDP-shRNA-EHD1 cells (Fig. 2h). The shRNA se-
quences efficiently knocked down the expression of
EHD1. Figure 2j shows the reduction in EHD1 mRNA in
response to EHD1 shRNA measured by RT-PCR. More
importantly, these findings are reminiscent of those in
clinical samples, in which EHD1 expression was intense
Table 1 Clinical characteristics of the NSCLC patients stratified
by EHD1 level
Characteristic Positive Negative P
Age (years)
High (≥60) 9 14 0.306
Low (<60) 19 17
Sex
Male 13 25 0.006
Female 15 6
Histology
Adenocarcinoma 26 17 0.001
Squamous cell carcinoma 2 14
Smoking status
Smokers 15 24 0.053
Non smokers 13 7
Differentiation
Well/Moderate 13 12 0.549
Poor 15 19
Stage (AJCC)
I,II 19 26 0.149
III,IV 9 5
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in the perinuclear area in the CDDP-resistant specimens
(Fig. 1a-d).
Overexpression of EHD1 confers cytoprotection against
CDDP in NSCLC cells
Figure 3a shows that the EHD1 levels were significantly
elevated in A549-EHD1 cells compared with the control,
as evidenced by a western blot analysis. We next con-
firmed the effect of EHD1 on the efficacy of CDDP by
stably overexpressing EHD1 in NSCLC cells. The indi-
cated cell lines were treated with increasing concentra-
tions (2, 4, 8, 16, 32 and 64 μM) of CDDP for 24 and
48 h before measuring inhibition. Cells that overex-
pressed EHD1 (A549-EHD1) exhibited higher survival
rates than the control line in response to increasing con-
centrations of CDDP (Fig. 3b and d). The A549-EHD1
cells were 3.3-fold(24 h) and 3.0-fold(48 h) more resist-
ant to cisplatin than the control cells, as determined by
their IC50 values, respectively (Fig. 3c and e). To exam-
ine the effects of CDDP on NSCLC cell apoptosis, the
cells were exposed to 0, 2.5, 5 or 10 μM CDDP for 24 h
and analysed by flow cytometry. In A549-control cells,
2.5, 5 and 10 μM CDDP increased the population of
apoptotic cells to 3.85, 7.55 and 17.06 %, respectively
(Fig. 3f, g). In contrast, the proportion of early apoptotic
cells only slightly increased in A549-EHD1 cells exposed
to 2.5 or 5 μM CDDP (3.04 and 4.06 %, respectively),
with the highest proportion (8.63 %) observed in the
10 μM CDDP treatment group (Fig. 3f, g). Overall, treat-
ment with CDDP induced apoptosis in NSCLC cells but
not in EHD1-overexpressing cells. Thus, the overexpres-
sion of EHD1 protected NSCLC cells from CDDP-
induced cell death and increased survival.
Knockdown of EHD1 enhances CDDP cytotoxicity in
NSCLC cells
Figure 4a shows that EHD1-shRNA considerably de-
creased EHD1 protein expression, as evidenced by a
western blot analysis. We next tested the effect of CDDP
inhibition on cell viability in CDDP-resistant NSCLC
Fig. 1 IHC analysis of EHD1 expression and correlation between EHD1 and survival in NSCLC tissues. EHD1-negative (a:x100; bx400:) and EHD1-
positive (c:x100;d:x400) tumour samples are shown. Tissue sections were stained with EHD1-specific antibodies, and an immunohistochemical
analysis was conducted as described in the Materials and Methods. e: OS in NSCLC patients receiving adjuvant chemotherapy. Patients receiving
post-operational adjuvant chemotherapy with positive EHD1 expression exhibited reduced OS (P = 0.01)
Table 2 Level of EHD1 gene upregulation in CDDP-resistant
NSCLC cells assessed by DNA microarray analysis
Gene Function Fold change
EHD1 EH domain-containing protein 1.3419
EHD1 EH domain-containing protein 1.2393
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cells. The indicated cell lines were treated with increas-
ing concentrations of cisplatin. After 24 and 48 h, CDDP
inhibition markedly reduced cell viability in the CDDP-
resistant cell line transfected with shRNA-EHD1 but did
not markedly affect control cells (Fig. 4b and d). More-
over, the IC50 values for CDDP were at least 5.2-
fold(24 h) and 3.6-fold(48 h) higher in A549 control cells
than in the A549-shRNA-EHD1 line, respectively (Fig. 4c
and e). We then examined differences in CDDP-induced
apoptosis between EHD1 knockdown cells and control
cells. Apoptosis in A549/DDP control and A549/DDP-
shRNA-EHD1 cells treated with 0, 2.5, 5 and 10 μM
CDDP for 24 h was assessed by flow cytometry. The
proportion of early apoptotic cells only slightly increased
in A549/DDP control cells exposed to 2.5, 5, 10 μM
CDDP (2.79, 3.03 and 8.23 %, respectively), but this
population significantly increased in EHD1 knockdown
cells treated with 5 (6.95 %) and 10 μM (16.69 %) CDDP
(Fig. 4f and g). The knockdown of EHD1 induced apop-
tosis in A549/DDP cells but not in control cells. More-
over, EHD1 knockdown significantly sensitized cells to
cisplatin, suggesting that EHD1 knockdown could re-
verse CDDP resistance and enhance cytotoxicity in
CDDP-resistant A549 cells.
EHD1 correlated with the intracellular CDDP
concentrations in NSCLC
The intracellular CDDP concentrations in NSCLC were
investigated using HPLC. The concentration of CDDP in
the cells was determined by measuring the total plat-
inum concentration. The relationship between the cis-
platin peak area and concentration was linear and
Fig. 2 Establishment of EHD1-overexpressing and EHD1-knockdown NSCLC cells. EHD1 was confirmed at both the transcript and protein level in
A549 and A549/DDP cell lines (a and b). The NSCLC cell line A549 was transfected with control or EHD1 overexpression (A549-EHD1) vector and
analysed for EHD1 expression by immunofluorescence (c-e) and qRT–PCR (i). The CDDP-resistant cell line (A549/DDP) transfected with control or
shRNA-EHD1 was analysed for EHD1 expression by immunofluorescence (f-h) and qRT–PCR (j)
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Fig. 3 (See legend on next page.)
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characterized by a correlation coefficient of 0.998
(Additional file 1: Figure S1). CDDP was added to a
blank cellular lysate, and the level of CDDP was moni-
tored. The statistical analysis of the data revealed the re-
covery of CDDP from cellular lysates and the relative
standard deviation of the assay (Additional file 2: Tables
S1 and 2). CDDP was not detected in the blank cellular
lysate samples. The indicated cell lines were exposed to
20 μM CDDP for 4, 8, 12 and 24 h and analysed in trip-
licate; Fig 5 shows one peak for cisplatin with a retention
time of approximately 8.2 min. Figure 5a and c show
chromatograms of CDDP in each cell line at the indi-
cated time points. Figure 5b and d show the time
courses of CDDP levels in each cell line. Specifically, the
concentration of CDDP positively correlated with time.
However, the increase in the CDDP concentrations of
the control was significantly higher than that observed
in EHD1-overexpressing A549 cells (Fig. 5a and b), and
the increase in the CDDP concentration in EHD1 knock-
down cells was significantly higher than that in A549/DDP
control cells (Fig. 5c and d). Interestingly, the concentra-
tions of CDDP extracted from the cell lines after 12 or 24 h
did not significantly differ, although the 24 h time point ex-
hibited higher concentrations of CDDP in each cell line
than the 12 h time point (A549-EHD1,A549/DDP-control,
A549/DDP-shRNA-EHD1). Thus, the indicated cell lines
were exposed to 10, 20 and 50 μM CDDP for 12 h and ana-
lysed in triplicate. The results show differences in the
CDDP concentrations between EHD1 overexpression and
control cells. In A549-EHD1 cells, the total platinum level
was lower than in control cells (Fig. 5e and f).
Similarly, high concentrations of CDDP were observed
in EHD1 knockdown cells, but low concentrations of
CDDP were observed in the control cells (Fig. 5g and h).
These results indicate that EHD1 regulates the intracel-
lular CDDP concentrations. The high concentration of
CDDP in EHD1 knockdown cells could explain the clin-
ical utility of CDDP in the treatment of NSCLC.
Discussion
For patients with resectable stage IB to IIIA NSCLC,
CDDP-based regimen is the most common choice for
postoperative adjuvant therapy, but its clinical effective-
ness is undermined by the inherent and acquired resist-
ance of tumour cells to this drug. In this study, we
observed that the expression of EHD1 was upregulated
in cisplatin-resistant NSCLC cells, as indicated by DNA
microarrays. Consequently, EHD1 expression predicted
a poor OS in patients who received adjuvant chemother-
apy. A previous study using DNA microarrays showed
the EHD1 gene was upregulated at least 2-fold in HeLa-
R1 cells or at least 4-fold in HeLa-R3 cells [7], and the
upregulation of EHD1 was reported to be associated
with cisplatin resistance. We favour the interpretation
that platinum-based chemotherapy is more effective
against EHD1-negative tumours. To further support
these data, we established EHD1 overexpression and
knockdown cell lines and then evaluated their response
to CDDP.
Indeed, NSCLC cells that stably overexpressed EHD1
exhibited strong resistance to cisplatin. Consistent with
these results, the IC50 value of CDDP in EHD1 knock-
down cells was at least 5.2-fold(24 h) and 3.6-fold(48 h)
lower than that in control cells, respectively. To under-
stand the mechanism underlying the protective effect
against CDDP-induced cytotoxicity, we examined the
population of early apoptotic cells in CDDP-treated
EHD1 overexpressing cells. The results suggest that the
percentage of early apoptotic cells was significantly de-
creased in A549-EHD1 cells. We also found that the
apoptosis index for A549/DDP cells remained low, but
the rates of early apoptosis were higher in the EHD1
knockdown cell line than in the A549/DDP control line.
These results suggest that knockdown of EHD1 sensi-
tized platinum complex-resistant NSCLC cells to CDDP,
but EHD1 overexpression might prevent CDDP-induced
apoptotic death to protect NSCLC cells from the effects
of CDDP. Specifically, our data suggest that the inhib-
ition of EHD1 is an effective method to overcome CDDP
resistance in NSCLC. These data have provided a novel
biomarker and insight into the mechanism of chemore-
sistance in NSCLC.
Resistance to CDDP is a major obstacle in the clinical
treatment of NSCLC. Multiple mechanisms are involved
in the cytotoxic effects of CDDP, and resistance is com-
monly believed to be associated with the decreased
intracellular accumulation of drugs [17]. The formation
of DNA adducts by cisplatin can be limited by reduced
drug accumulation in a tumour cell. By fluorescence mi-
croscopy, we found that EHD1 was expressed in the
cytoplasm, forming a ring-like pattern at the nuclear
periphery. Similarly, ERC is expressed near the nucleus.
(See figure on previous page.)
Fig. 3 Overexpression of EHD1 confers resistance to CDDP in NSCLC cells. a Western blotting analysis to confirm the overexpression of EHD1.
GAPDH was used as a control to verify the equal loading of protein. Relative protein levels of EHD1 were determined. b Inhibitory effect of CDDP
was measured in NSCLC cells using the CCK-8 assay at 24 h. c The IC50 values for CDDP were determined in NSCLC cells at 24 h. d Inhibitory
effect of CDDP was measured at 48 h. e The IC50 values for CDDP were determined at 48 h. f Annexin-V-FITC/PI staining was analysed by flow
cytometry in NSCLC cells after treatment with CDDP for 24 h. g The histogram demonstrates the percentage of early apoptotic NSCLC cells in
response to CDDP concentrations of 0, 2.5, 5 and 10 μM
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Fig. 4 (See legend on next page.)
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(See figure on previous page.)
Fig. 4 Knockdown of EHD1 increased sensitivity to CDDP in CDDP-resistant NSCLC cells. a Western blotting analysis of EHD1 levels. b Inhibitory
effect of CDDP was measured in CDDP-resistant NSCLC cells using the CCK-8 assay at 24 h. c The IC50 values for CDDP were determined in
CDDP-resistant NSCLC cells at 24 h. d Inhibitory effect of CDDP was measured at 48 h. e The IC50 values for CDDP were determined at 48 h.
f Annexin-V-FITC/PI staining was analysed by flow cytometry in CDDP-resistant NSCLC cells after treatment with CDDP for 24 h. g The histogram
demonstrates the percentage of early apoptotic in CDDP-resistant NSCLC cells in response to CDDP concentrations of 0, 2.5, 5 and 10 μM
Fig. 5 Determination of the CDDP concentrations in NSCLC cells treated with CDDP. a Chromatograms of extract (CDDP) from NSCLC cellular lysate
(4, 8, 12, and 24 h). b Quantification of CDDP in lysate extracted from EHD1-overexpressing and control cell lines (4, 8, 12, and 24 h). c Chromatograms
of extract (CDDP) from CDDP-resistant NSCLC cellular lysate (4, 8, 12, and 24 h). d Quantification of CDDP in lysate extracted from EHD1 knockdown
and control cell lines (4, 8, 12, and 24 h). e Chromatograms of extract (CDDP) from NSCLC cellular lysate (10, 20, and 50 μM). f Quantification of CDDP
in lysate extracted from EHD1-overexpressing and control cell lines (10, 20, 50 μM). g Chromatograms of extract (CDDP) from CDDP-resistant NSCLC
cellular lysate (10, 20, and 50 μM). h Quantification of CDDP in lysate extracted from EHD1 knockdown and control cell lines (10, 20, and 50 μM)
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Thus, EHD1 co-localizes with ERC, suggesting its partici-
pation in cargo internalization [9]. Endocytosis can be
classified into several types, including macropinocytosis,
clathrin-mediated endocytosis and caveolin- mediated
endocytosis [18]. A rapid recycling pathway transports
cargo directly from the EE to the plasma membrane,
whereas a second, slower pathway involves passage
through the ERC [19]. The primary role of EHD1 appears
to be in regulating the return of endocytosed cargo to the
plasma membrane from ERC via a clathrin-dependent
pathway [19]. However, the mechanisms are complex and
not yet completely understood. EHD1 might associate
with the cargo vesicles arriving from the early endosome
on ERC membranes and link them to motor proteins [20].
The motor proteins would then drive these cargo vesicles
for delivery back to the cell surface. Alternatively, EHD1,
which exhibits ATPase activity, may promote the budding
of vesicles from tubules that emanate from the ERC, thus
facilitating vesicular transport to the cell surface [20].
Endocytic recycling has long been regarded as a trafficking
route, and this process is important in the control of mul-
tiple signalling pathways and biological functions [21]. Re-
sistance to cisplatin is likely due to the up-regulation of
EHD1, which increases the trafficking of CDDP from the
ERC to the plasma membrane and limits the ability of cis-
platin to form DNA adducts in the nucleus. Similarly, the
recycling of internalized CDDP to the cell surface is de-
creased in EHD1-depleted cells.
In this study, we sought to investigate the effect of
EHD1 on CDDP accumulation. The HPLC method was
successfully applied to in vitro studies and enabled us to
quantify CDDP not only in the NaCl medium but also in
the cellular lysates using only 0.02 mL of a sample. Our
results clearly demonstrate that the intracellular CDDP
concentrations in EHD1-overexpressing cells were lower
than those in control cells. The cellular accumulation of
CDDP, as measured by HPLC, was not significantly re-
duced in CDDP- resistant cells. However, the knockdown
of EHD1 increased the intracellular accumulation of
CDDP, which may effectively prevent drug release from
cells and be related to the reduced excretion of CDDP.
This findings suggests that EHD1 significantly affects the
cellular accumulation of CDDP and consequently is an
important determinant of the cytotoxicity of CDDP. The
use of this HPLC system can unambiguously measure the
level of CDDP in cells. This technique will be suitable for
the quantitative determination of CDDP in cancer cells
showing resistance and requires minimal sample prepar-
ation. Thus, this method is easily automated and will be
useful for studies of drug therapies.
Conclusion
These observations indicate that the overexpression of
EHD1 reduced the accumulation of CDDP in the cell,
significantly inhibiting adduct-induced apoptosis and
contributing to drug resistance in NSCLC cells. The
knockdown of EHD1 sensitizes cells to chemotherapy
and reverses CDDP resistance in lung cancer cells via
the accumulation of CDDP inside cells. Overall, these
findings indicate that EHD1 is a tumour resistance-
associated protein. Therefore, EHD1-targeted therapy
may improve the treatment of CDDP-resistant tumours
to increase survival in patients with lung cancer.
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